FDA
-
-
-
-
-
-
-
Cybin (CYBN) Initiates Phase 2 Proof-of-Concept Study of CYB004
-
-
-
-
-
-
-
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
-
-
-
-
-
-
-
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
-
-
-
-
-
-
-
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
-
-
-
-
-
-
-
Cybin Inc (CYBN) Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
-
-
-
-
-
-
-
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
-
-
-
-
-
-
-
Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
-
251,757 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All